Parameters | P value | HR | HR(95% CI) |
---|---|---|---|
Male | 0.199 | 1.505 | 0.806–2.807 |
Age ≥ 60 years | < 0.001 | 4.430 | 2.406–8.157 |
Hypertension | < 0.001 | 4.591 | 2.134–9.878 |
Albumin(g/L) | |||
 ≥ 30 |  |  | 1.00 (referent) |
 20–29.9 | 0.965 | 1.020 | 0.414–2.517 |
  ≤ 19.9 | 0.289 | 1.674 | 0.646–4.339 |
Urine protein content(g/24 h) | |||
  < 3.9 |  |  | 1.00 (referent) |
 4–7.9 | 0.962 | 1.017 | 0.511–2.023 |
  ≥ 8 | 0.258 | 1.549 | 0.725–3.311 |
Serum creatinine≥134(umol/L) | < 0.001 | 16.888 | 8.164–34.932 |
eGFR< 60(ml/min per 1.73 m2) | < 0.001 | 9.509 | 5.178–17.460 |
FSL (FSGS,aFSL = 1,FSL− = 0) | < 0.001 | 3.822 | 1.961–7.447 |
FSL | |||
 FSL− |  |  | 1.00 (referent) |
 FSGS | < 0.001 | 6.902 | 3.493–13.635 |
 aFSL | 0.914 | 0.939 | 0.302–2.919 |
Stage | |||
 I |  |  | 1.00 (referent) |
 II | 0.31 | 1.455 | 0.706–2.998 |
 III and IV | 0.237 | 1.705 | 0.704–4.133 |
Global glomerulosclerosis (> 5%) | < 0.001 | 5.212 | 2.680–10.136 |
Proliferation of mesangial area | |||
 0 |  |  | 1.00 (referent) |
 1 | 0.034 | 2.095 | 1.059–4.147 |
 2 and 3 | 0.061 | 2.741 | 0.956–7.858 |
Tubulointerstitial fibrosis (area ≥ 15%) | < 0.001 | 7.368 | 4.050–13.404 |
Vascular sclerosis | |||
 0 |  |  | 1.00 (referent) |
 1 | 0.036 | 4.725 | 1.104–20.223 |
 2 | 0.002 | 10.617 | 2.440–46.203 |
 3 | < 0.001 | 30.771 | 6.141–154.175 |